SPS
CCCC icon

Susquehanna Portfolio Strategies’s C4 Therapeutics CCCC Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$685K Sell
260,279
-11,774
-4% -$27.7K 0.01% 703
2025
Q4 		$520K Hold
272,053
– – 0.01% 777
2025
Q3 		$604K Buy
272,053
+145,153
+114% +$348K 0.01% 785
2025
Q2 		$181K Buy
+126,900
New +$185K ﹤0.01% 803
2024
Q2 		– Sell
-91,127
Closed -$745K – 558
2024
Q1 		$745K Hold
91,127
– – 0.02% 515
2023
Q4 		$515K Buy
+91,127
New +$208K 0.01% 759

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna Portfolio Strategies's CCCC Position: Q1 2026 in Review

Susquehanna Portfolio Strategies reduced its C4 Therapeutics (CCCC) stake by 4.3% in Q1 2026, selling an estimated $27.7K and leaving 260,279 shares worth $685K. The position accounts for 0.01% of the portfolio, ranked #703.

Susquehanna Portfolio Strategies first reported a position in CCCC in Q4 2023 and has held it in 6 quarters since. The position peaked at $745K in Q1 2024. 123 funds tracked by Wall St. Rank hold CCCC as of Q1 2026.

  • Susquehanna Portfolio Strategies held 260,279 shares of C4 Therapeutics worth $685K as of Q1 2026.
  • Susquehanna Portfolio Strategies sold 11,774 C4 Therapeutics shares in Q1 2026, an estimated $27.7K.
  • C4 Therapeutics made up 0.01% of Susquehanna Portfolio Strategies's portfolio in Q1 2026, its #703 holding.
  • Susquehanna Portfolio Strategies first reported a position in C4 Therapeutics in Q4 2023 and has held it in 6 quarters since.
  • Susquehanna Portfolio Strategies's C4 Therapeutics position peaked at $745K in Q1 2024.
  • 123 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q1 2026, filed 15 May 2026.